Related Experiment Video

Updated: May 31, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Urokinase receptor (uPAR) ligand based recombinant toxins for human cancer therapy

Maddalena de Virgilio1, Franco Silvestris

  • 1Institute of Plant Genetics, National Council of Research, Via Amendola 165/A, 70126 Bari, Italy. maddalena.devirgilio@igv.cnr.it

Current Pharmaceutical Design
|June 30, 2011
PubMed

Insights

Researchers developed novel chimeric toxins targeting cancer cells by linking a urokinase receptor (uPAR) targeting domain to potent toxins. These engineered proteins show therapeutic potential against various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • The urokinase receptor (uPAR) plays a critical role in cancer progression, making it a significant therapeutic target.
  • Targeting uPAR offers a promising strategy for developing novel anti-cancer drugs.

Purpose of the Study:

  • To review the design, production, and anti-cancer potential of chimeric toxins engineered to target uPAR.
  • To explore the therapeutic applications of fusion proteins combining uPAR-binding domains with cytotoxic agents.

Main Methods:

  • Design of recombinant toxins, including DTAT, DTAT13, EGFATFKDEL 7 mut, and ATF-SAP.
  • Utilizing the amino-terminal fragment of urokinase (uPA N-terminal fragment) as a molecular address for uPAR targeting.
  • Incorporating various toxin moieties from diphtheria toxin, Pseudomonas exotoxin A (PE38), or saporin.

Main Results:

  • Successful design and production of several chimeric toxins targeting uPAR.
  • Demonstration of the therapeutic anti-cancer potential of these novel agents.

Conclusions:

  • Chimeric toxins targeting uPAR represent a promising new class of anti-cancer therapeutics.
  • The combination of specific targeting and potent cytotoxicity offers a viable strategy for tumor cell elimination.

More Related Videos

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter07:53

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter

Published on: April 17, 2026

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...